Sinopharm CNBG COVID-19 vaccine

Sinopharm CNBG COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration
Intramuscular
Legal status
Legal status

Sinopharm CNBG COVID-19 vaccine is a COVID-19 vaccine developed by China National Biotec Group (CNBG), a subsidiary of Sinopharm.[1][2]

They claim to be the world's first "second generation" protein recombination vaccine.[3]

References

  1. "Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE". Gulf News. 27 December 2021. Retrieved 27 December 2021.
  2. "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved 5 May 2021.
  3. 國藥集團:二代重組蛋白新冠疫苗保護效果良好


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.